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Abstract
Listeria monocytogenes is the causative agent of human listeriosis, a potentially fatal foodborne infection. Clinical manifestations range
from febrile gastroenteritis to more severe invasive forms, including sepsis, meningitis, rhombencephalitis, perinatal infections, and abor-
tions. In recent years, an increasing rate of listeriosis has been reported in several European countries. These increases primarily reﬂect
a higher rate of bacteraemic listeriosis in those ‡65 years of age, and are not otherwise correlated with geography, gender, ethnicity,
socioeconomic factors or infectious serotypes. In the late 1980s, an upsurge in listeriosis rates was due to the contamination of a small
number of food products. However, a restricted range of strains was responsible for most of the additional cases at that time, and no
evidence exists for such a pattern since 2001. From a clinical perspective, the importance of isolating the pathogen as a prerequisite for
an accurate epidemiological investigation and ultimately stopping transmission cannot be overemphasized.
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Introduction
Listeriosis is a rare but potentially serious infection caused
by Listeria monocytogenes. This organism can be found
throughout the environment in soil, vegetation and animals.
The main route of transmission is believed to be through
consumption of contaminated food. However, infection can
also be transmitted, albeit very rarely, directly from
infected animals to humans, as well as between humans [1].
In neonatal infections, L. monocytogenes can be transmitted
from mother to child in utero or during passage through
the infected birth canal. There are also rare reports of nos-
ocomial transmission attributed to contaminated material or
patient-to-patient transmission via healthcare workers [1].
The bacterium is particularly successful in causing food-
borne disease, because it survives food-processing technolo-
gies that rely on acidic or salty conditions [2], and, unlike
many pathogens, can continue to multiply slowly at low
temperatures, allowing for growth even in properly refriger-
ated foods.
In recent years, an increasing rate of listeriosis has been
reported in several European countries [3–10]. These
increases primarily reﬂect a higher rate of bacteraemic liste-
riosis in those ‡65 years of age, and are not otherwise
correlated with geography, gender, ethnicity, socioeconomic
factors or infectious serotypes [6,7]. The Annual Epidemiolog-
ical Report on Communicable Diseases in Europe 2008 states:
‘‘There appears to have been a signiﬁcant increasing trend in
the listeriosis notiﬁcation rate in the EU from 2003 to 2006’’
[11]. Half (53.8%) of the EU member states with conﬁrmed
cases also reported an increasing trend during the 2-year per-
iod 2006–2007 [12]. The cause of this increasing incidence,
which, as shown in Fig. 1, was still ongoing in 2008, in Austria
at least, is unknown. A total of 1554 conﬁrmed cases of liste-
riosis were reported from 26 EU member states in 2007. The
EU notiﬁcation rate was 0.3 per 100 000 population [12].
Incidences for six EU countries are given in Fig. 2 [13].
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Clinical Manifestations
L. monocytogenes causes two forms of listeriosis: non-invasive
gastrointestinal listeriosis and invasive listeriosis. In immuno-
competent individuals, non-invasive listeriosis develops as a
typical febrile gastroenteritis. In immunocompromised adults,
such as the elderly and patients receiving immunosuppressive
agents, listeriosis can manifest as septicaemia or meningoen-
cephalitis. Invasive listeriosis can also be acquired by the
fetus from its infected mother via the placenta [13]. Perinatal
listeriosis can lead to abortion, birth of a stillborn fetus or a
baby with generalized infection (granulomatosis infantiseptica),
and sepsis or meningitis in the neonate. Neonatal listeriosis
is subdivided into two clinical forms: early-onset (usually
deﬁned as occurring within the ﬁrst week of life) and late-
onset. The late-onset type may occur from one to several
weeks after birth.
Listeriosis during pregnancy is a serious threat to the
unborn child. One-third of culture-conﬁrmed cases of mater-
nal–fetal infections result in abortion or stillbirth. However,
the prognosis for live-born babies is good, even in those
severely ill [10]. Pregnancy-associated cases refer to listerio-
sis in pregnant women or in the neonates (up to 28 days of
life), and the non-pregnancy-associated cases to older babies
(>28 days) [1]. Most maternal infections occur during the
third trimester of pregnancy, when T-cell immunity is most
impaired. Infected women typically develop non-speciﬁc ﬂu-
like symptoms but may remain asymptomatic. Listeriosis has
rarely been observed during the ﬁrst trimester [14].
In non-pregnancy-associated cases, listeriosis mainly mani-
fests as meningoencephalitis or septicaemia. The median
incubation period is estimated to be 3 weeks. Outbreak
cases have occurred 3–70 days following a single exposure
to an implicated product. The onset of meningoencephalitis,
which is rare in pregnant women, can be sudden, with fever,
intense headache, nausea, vomiting and signs of meningeal
irritation, or may be subacute, particularly in an immunocom-
promised or elderly host. Rhombencephalitis involving the
brainstem is an unusual form of listeriosis. L. monocytogenes
can also produce a wide variety of focal infections; cases of
conjunctivitis, skin infection, lymphadenitis, hepatic abscess,
brain abscess, cholecystitis, peritonitis, splenic abscess,
pleuropulmonary infection, joint infection, osteomyelitis,
pericarditis, myocarditis, arteritis, necrotizing fasciitis and
endophthalmitis have been described [1,15–18]. In Europe,
approximately 10–20% of clinical cases are pregnancy-associ-
ated (including neonates within the ﬁrst 4 weeks of birth),
but the majority of cases occur in non-pregnant immuno-
compromised individuals, especially the elderly. Approxi-
mately 10% of patients have no known risk factor or
underlying disease predisposing them to infection with Listeria
[6]. In Austria in 1997–2007, patients without known risk
factors ranged in age from 1 to 64 years (average,
45.2 years; median, 46.6 years). The overall mean age of the
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FIG. 1. Absolute number of cases of invasive
listeriosis, Austria 1997–2008 (n = 181).
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FIG. 2. Listeriosis incidence in six EU countries, 1999–2007 (modi-
ﬁed from Eurosurveillance, with permission).
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Austrian non-pregnancy-associated listeriosis patient in that
period was 64.3 years (median, 66.2 years; range, 0.8–
93.5 years), i.e. signiﬁcantly greater than the age of patients
with underlying diseases [6].
Epidemiology and Transmission
Outbreak cases
Clusters, suspected or conﬁrmed to represent community
outbreaks, have contributed to the recent increased inci-
dence in some countries. In 2005, ten cases of listeriosis in a
small area of Switzerland were due to locally made and dis-
tributed soft cheese [19]. In 2006, the Czech Republic expe-
rienced one large outbreak, involving 78 patients, of whom
13 died; here also, soft cheese was identiﬁed as the source
[3]. During the period 2006–2007, Germany recorded an
outbreak of 16 cases caused by presliced ready-to-eat (RTE)
delicatessen meat (sausage salad) (International Meeting on
Emerging Diseases and Surveillance, 2009, Abstract 10.098).
In 2008, Austria experienced an outbreak of febrile gastro-
enteritis, including three cases of invasive listeriosis associ-
ated with jellied pork contaminated with L. monocytogenes
[20]. However, the overall proportion of cases related to
clusters remained stable and low; therefore, these clusters
did not account for the increased incidence in Austria.
Sporadic cases
Whereas much has now been learned about epidemic listeri-
osis, little is known about sporadic listeriosis, which, in fact,
represents the majority of cases [5]. Dietary risk factors for
sporadic listeriosis have been assessed through case–control
studies. In a study conducted during the period 1986–1987
in the USA, case patients were signiﬁcantly more likely than
controls to have eaten uncooked or non-reheated hot dogs
(frankfurters) or undercooked chicken. An estimated 20% of
the overall risk of listeriosis was thought to be attributable to
consumption of these foods [21]. Another study performed
in the USA from 1988 to 1990 found that case patients were
signiﬁcantly more likely than controls to have eaten soft
cheeses or delicatessen foods [22]. Other exposures associ-
ated with an increased risk of sporadic disease included
recent use of antacids, laxatives or H2-receptor antagonists
[22]. Dietary risk factors for sporadic listeriosis were also
examined in a study in Denmark; drinking unpasteurized milk
or eating pate´ were the only risk factors identiﬁed [23].
Although listeriosis is said to be 100–1000 times more
common in patients with AIDS than in the age-matched gen-
eral population, it is somewhat surprising that it is not seen
more commonly, given the ubiquity of the organism. Among
181 cases of invasive listeriosis documented in Austria from
1997 until 2008, only one patient was human immunodeﬁ-
ciency virus-positive [6] (unpublished data, F.A.). A partial
explanation may lie in the experimental observation that
resistance to listeriosis appears to be mediated by lym-
phocytes that do not carry CD4 or CD8 markers [24].
In addition, it is likely that many cases are prevented by
routine Pneumocystis jirovecii prophylaxis with trimethoprim–
sulphamethoxazole.
Diagnosis of Listeriosis
Listeriosis is diagnosed by a positive culture from a normally
sterile site. L. monocytogenes can be readily cultured from
clinical specimens such as blood, cerebrospinal ﬂuid (CSF),
amniotic ﬂuid, placenta, meconium, lochia, gastric washings
or ear swabs from newborns, by directly plating the material
onto blood agar plates and incubating overnight at 35C in
an ambient atmosphere. Stool specimens (other than meco-
nium) should be selectively enriched for Listeria before being
plated on selective agar media. Classic cold enrichment over
months is no longer necessary. PCR is the only test utilized
for rapid detection of L. monocytogenes in clinical specimens.
The PCR assay is particularly useful when prior administra-
tion of antimicrobial agents is likely to compromise culture.
Various test protocols were evaluated for CSF samples
and tissue samples (fresh or in parafﬁn blocks). Gram staining
and microscopic examination of CSF or meconium permit
only a presumptive diagnosis. For clinical specimens, the
importance of isolating the pathogen as a prerequisite for
an epidemiological investigation and appropriate infection
control cannot be overstressed [25].
Because listeriosis during pregnancy is serious and difﬁcult
to diagnose, blood cultures should be considered for any
pregnant woman presenting with fever, especially if accompa-
nied by ﬂu-like or gastrointestinal symptoms [26]. Vaginal or
stool cultures are not helpful in diagnosis, because some
women are asymptomatic carriers [26]. Indeed, faecal car-
riage of L. monocytogenes occurs in 1–15% of the population
[27]; the incidence of women carrying L. monocytgenes in the
vagina is lower [26].
Listerial rhombencephalitis is a rare manifestation of liste-
riosis. In contrast to other listerial infections of the central
nervous system (CNS), the majority of listerial rhomben-
cephalitis cases occur in previously healthy adults; no cases
have been reported in infants [28]. Blood cultures may or
may not reveal growth of the organism in these cases.
Serological responses to commercially available whole cell
antigens (Gruber–Widal reaction using L. monocytogenes
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suspensions O and H) are not diagnostic, because of anti-
genic cross-reactivity between L. monocytogenes and other
Gram-positive bacteria such as staphylococci, enterococci
and Bacillus species [29]. Furthermore, patients with culture-
conﬁrmed listeriosis have been known to have undetectable
antibody levels. Positive serological ﬁndings must be treated
with caution and, in cases other than rhombencephalitis,
exact diagnosis should be based on detection of the patho-
gen. Serological responses to listeriolysin O (LLO) are sup-
posed to be more reliable [30]. An ELISA for the detection
of anti-LLO IgG in human serum and plasma is commercially
available (DIATHEVA, Fano, Italy). LLO, a polypeptide pro-
tein secreted by L. monocytogenes, is a major virulence factor
produced by all pathogenic L. monocytogenes strains but
released in the culture medium only at low levels. For this
reason, the LLO protein, used in the DIATHEVA assay as
test antigen, is expressed in Escherichia coli.
Treatment of Listeriosis Patients
In vitro, L. monocytogenes is susceptible to a wide range of
antibiotics, with the exception of fosfomycin, ﬁrst-generation
quinolones and third-generation cephalosporins, although a
few exceptional strains exist. Susceptibility testing is usually
performed using Mueller–Hinton agar, with or without blood
(5% horse blood or 5% sheep blood) [31]. For trimetho-
prim–sulphamethoxazole, the blood is lysed. Antimicrobial
in vitro susceptibilities of Listeria have not changed markedly
over the past 35 years [31,32]. Although optimal therapy has
not been veriﬁed by randomized clinical studies, penicillin
or ampicillin alone, or in combination with gentamicin, are
considered to be the drugs of choice. The clinically effective
antibiotics penicillin and ampicillin are only bacteriostatically
effective against L. monocytogenes, thus emphasizing the impor-
tance of the body’s own cellular defence mechanisms [33].
Addition of gentamicin has not been proven to be clini-
cally advantageous, as synergy has only been demonstrated
in vitro [34]. Moreover, in animal models, gentamicin does
not reliably show a synergistic effect [35]. A gentamicin-
supplemented protocol should not be prescribed for preg-
nant women, because of possible teratogenic effects [2,33].
As Listeria does not produce b-lactamase, the addition of
b-lactamase inhibitors in the treatment of listeriosis is
ineffective. There is no relevant difference between the MIC
values of ampicillin alone and ampicillin combined with
sulbactam for the treatment of infection due to L. monocyto-
genes [32] .
For patients with b-lactam allergy, trimethoprim–sulpha-
methoxazole or erythromycin may be considered. Steps
should be taken to establish and document true penicillin
allergy prior to starting treatment with these second-line
agents. Transplacental passage of erythromycin has been
shown to provide subtherapeutic concentrations in both the
amniotic ﬂuid and fetal serum [36]. Therefore, many experts
recommend using an alternative. Vancomycin has also been
used in cases of bacteraemic listerial infection [37]. However,
the results obtained from a model of rhombencephalitis in
gerbils strongly suggest that intravenous vancomycin is unli-
kely to be effective in patients with CNS infection [35]. Lin-
ezolid is another agent that has been used successfully to
treat listerial infections [38]. Other antibiotics used in cases
of listeriosis include meropenem and rifampicin [39]. It has
been speculated that, at least in the immunocompromised
host, the addition of rifampicin, which is effective against
intracellular L. monocytogenes and will penetrate the CSF,
could help to eradicate residual bacteria [32]. Resistance has
been reported with rifampicin monotherapy [33]. Kayser
et al. [40] reported, as early as 1989, good in vitro activity of
meropenem. Another study with this antibiotic showed good
activity in experimental meningitis in guinea pigs [41].
L. monocytogenes reproduces in the reticuloendothelial sys-
tem and survives intracellularly after uptake by macrophages
[33]. The bone marrow might be a unique niche for L. mono-
cytogenes [42]. This means that the organism cannot be
reached by certain antibiotics; this might contribute to the
differences between in vitro and in vivo results. Macrolides
and quinolones accumulate within host cells and may attack
the intracellular Listeria organisms. Moxiﬂoxacin may be a
promising candidate; however, no clinical trials have provided
ﬁrm evidence [43]. L. monocytogenes is intrinsically resistant
to nalidixic acid (MIC >128 mg/L) and shows decreased sus-
ceptibility to therapeutically important ﬂuoroquinolones, such
as ciproﬂoxacin (MIC 0.5 – 2 mg/L) [44]. In an animal model,
ciproﬂoxacin was only weakly active in the spleen, liver and
CNS [35]. However, the newer derivatives of the quinolones
(e.g. levoﬂoxacin and moxiﬂoxacin) exhibit strong bacterici-
dal activity against L. monocytogenes [45,46].
Antimicrobial drugs that are of questionable value in ani-
mal experiments or for the treatment of human listeriosis
include clindamycin and aminoglycosides when administered
individually [33]. Cephalosporins have hardly any in vitro
effect against L. monocytogenes. The reason is the minimal or
non-existent afﬁnity of listerial penicillin-binding proteins 3
and 5 for cephalosporins [47]. Despite good in vitro activity,
even cephalothin had no effect on experimental listeriosis in
mice [33]. In addition, cephalothin lacks satisfactory CSF pen-
etration. Reports of therapeutic failures prove that cephalo-
sporins are not indicated for the treatment of listeriosis
[48].
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Fosfomycin was previously considered to be ineffective in
treating listeriosis, as revealed by in vitro laboratory data
[33]. Therefore, despite achieving theoretically excellent con-
centrations in brain and other tissues, fosfomycin has not
been used in the management of listeriosis. However, in
1979, a report demonstrated that fosfomycin might have a
positive effect on L. monocytogenes infections in mice [49].
Recent research has demonstrated that the effect of fosfo-
mycin on L. monocytogenes is dependent on the expression of
the Hpt protein encoded by the hpt gene, which is under the
control of the central virulence regulator protein PrfA. Hpt,
an organophosphate–inorganic phosphate anti-reporter,
enables L. monocytogenes to use hexose phosphates from the
host cell cytosol as an energy source, enabling intracellular
movement. As the virulence regulator gene prfA is switched
off extracellularly, Hpt becomes downregulated and L. mono-
cytogenes is resistent to fosfomycin in in vitro suceptibility
tests. However, upon upregulation of the virulence regulon
during infection, L. monocytogenes becomes susceptible to
fosfomycin. BALB/C mice, as used in in vivo tests, survived a
challenge of 108 CFUs per mouse, whereas the LD50 in con-
trols was 1.77 · 104 CFUs of L. monocytogenes [50].
It is generally recommended that patients should be trea-
ted for at least 14 days [33]. Even if a host appears to be
clinically improved, the intracellular concentration resulting
from short-course antibiotic treatment may not be sufﬁcient
for complete sterilization. Indeed, in immunosuppressed
patients, relapses have been reported after 2 weeks of peni-
cillin therapy [51]. In pregnancy, there are additional consid-
erations, such as adequate treatment of the placenta, and
potential ongoing infection of the fetus or placenta. There
has been concern that placental infection may not be clini-
cally apparent, but could progress once antibiotic therapy
has been withdrawn. For this reason, some experts have sug-
gested at least 3–4 weeks of treatment during pregnancy
[37]. Patients with rhombencephalitis should be treated with
antibiotics for at least 6 weeks [28].
Although there are no data concerning the efﬁcacy of anti-
microbials in listerial gastroenteritis, it could be argued that,
in both symptomatic and asymptomatic persons known to
have ingested a food implicated in an outbreak, and who
have a high risk of invasive disease because of underlying
illness, pregnancy or age (elderly), it might be prudent to
administer oral amoxycillin or trimethoprim–sulphamethox-
azole for 7 days [20]. Recently developed protocols employ-
ing gerbils and genetically engineered mice now allow the
effect of antibotics to be studied in animal models relevant
to humans [52].
The CLSI has not yet provided speciﬁc guidelines for in vitro
susceptibility testing of Listeria. Apart from penicillin,
ampicillin and trimethoprim–sulphamethoxazole, for which
clinical CLSI breakpoints for Listeria susceptibility testing are
deﬁned, the usual CLSI criteria for staphylococci are applied
[53,54].
Immunization/Chemoprophylaxis
At present, there is no immunization available for listeriosis.
Engineered live-attenuated L. monocytogenes, which elicits
strong cellular immune responses, is currently being evalu-
ated in clinical trials as an anticancer vaccine [55]. The utility,
or even the feasibility, of eradicating gastrointestinal coloniza-
tion to prevent invasive listeriosis is unexplored. However,
asymptomatic individuals at high-risk of listeriosis, who are
known to have ingested a food implicated in an outbreak,
could reasonably be given 7 days of oral ampicillin or
trimethoprim–sulphamethoxazole treatment [20,56].
Discussion
Listeriosis is essentially a foodborne disease, and this is no
longer questioned. The upsurge in listeriosis rates in the late
1980s was due to contamination of a variety of food prod-
ucts, including coleslaw, unpasteurized milk and Mexican-style
soft cheese [1]. A restricted range of strains was responsible
for most of the additional cases at that time, and most
human cases are still associated with L. monocytogenes sero-
vars 1/2a, 1/2b and 4b. Whereas the number of reported
cases was quite stable during the period 1996–2002, an
increase was observed again during the period 2003–2007.
Currently, it appears that the numbers of cases of listeriosis
are stable in some countries, or, as in Germany, have
returned to those recorded previously.
The reasons for the changing incidence of listeriosis
remain unclear. No evidence exists for a causative role of
gradual demographic or behavioural changes. Cairns and
Payne [7] postulated that this phenomenon might be a
consequence of changes in government policy regarding busi-
ness practices that have had widespread effects on food pro-
cessing, distribution and preparation. Goulet et al. [5]
hypothesized that the recently reduced salt content in RTE
products may contribute to the growth of the organism, if
present as a contaminant, and increase the likelihood of
infection when these products are consumed by susceptible
individuals. The food industry reduced the salt content of
selected products, such as RTE meat products, in response
to recommendations in 2002 from food safety agencies, ask-
ing for a 20% reduction in average salt intake, spread over
20 Clinical Microbiology and Infection, Volume 16 Number 1, January 2010 CMI
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 16–23
5 years, in order to prevent disease attributable to hyperten-
sion-related conditions. Wagner et al. [57] studied samples
of RTE foodstuffs in Vienna, Austria. They found 4.8% of 946
samples collected from 103 supermarkets to be positive for
L. monocytogenes, with ﬁve smoked ﬁsh samples exceeding
the tolerated limit of 100 CFUs per gram of food. Products
showing the highest contamination rate were ﬁsh and sea-
food (19.4%), followed by raw meat sausages (6.3%), soft
cheese (5.5%) and cooked meat products/pate´s (4.5%). The
overall contamination rate of 640 RTE foodstuffs collected at
the household level was 1.7%. Importantly, most high-risk
foods were collected from households of elderly individuals.
Pulsed-ﬁeld gel electrophoresis typing of the collected
L. monocytogenes isolates revealed a high degree of diversity
among the isolates collected at the household level. More-
over, evidence from EU-wide routine food safety investiga-
tions indicates that a substantial proportion of RTE products
may be contaminated by L. monocytogenes [12]. L. monocytoge-
nes was detected in 1.8% of RTE meat products and meat
preparations of beef tested in 2007 (in 0.7% with
>100 CFUs/g), in 2.5% of RTE products and meat prepara-
tions of pork (in 0.6% with >100 CFUs/g), in 2.6% of RTE
products and meat preparations of poultry (in 0.7% with
>100 CFUs/g), in 1% of soft and semi-soft cheeses made
from raw or low-heat-treated milk (in 0.3% with
>100 CFUs/g), and in 18.3% of RTE ﬁsh products (2.4% with
>100 CFUs/g) [12]. It is therefore essential to control foods
that permit L. monocytogenes to grow to numbers exceeding
the arbitrarily deﬁned minimal infectious dose of 105 CFUs
per gram or millilitre of foodstuff. However, the dose–
response relationship remains unclear [58]. Strain-speciﬁc dif-
ferences in virulence seem to be of the utmost importance.
Newer risk assessment modelling suggests a 10)9 to 10)13
probability of infection with a dose of 100 organisms, and a
10)6 to 10)9 probability of infection at 1 000 000 organisms
[58].
Although exposure to L. monocytogenes cannot be avoided
completely, proper food preparation and storage can
decrease the risk. Pregnant women and immunocompro-
mised individuals should be advised to avoid consumption of
raw milk, unpasteurized soft cheeses, delicatessen meats, hot
dogs that are not adequately heated, refrigerated pate´s, and
smoked seafood, because they can be contaminated at a high
level [2]. Avoiding cross-contamination is also an important
protective strategy; all utensils and surfaces should be
washed well after preparation of meat or cutting of prepared
foods [2]. No clear evidence exists for the speciﬁc inclusion
of listeriosis in pre-conception care [59]. In addition to indi-
vidual advice to consumers, control of listeriosis requires
action from public health agencies and from the food industry.
Important control strategies from public health agencies
include developing and maintaining timely and effective disease
surveillance programmes, as well as promptly investigating
clusters of listeriosis cases. Routine characterization of
human, food and environmental isolates, and utilization of
large-scale subtype databases, will hopefully facilitate Europe-
wide outbreak detection and control in the near future [60].
Conclusions
L. monocytogenes has been recognized as a human pathogen
for more than 80 years. The demographic shift and the wide-
spread use of immunosuppressive medications, to treat
malignancy and manage organ transplantation, have increased
the immunocompromised population at increased risk of lis-
teriosis. Moreover, consumer lifestyles have changed, such
that less time is available for food preparation and more RTE
and takeaway foods are consumed. Changes in food produc-
tion and technology have led to the production of foods with
longer shelf-lives that are typical ‘Listeria-risk foods’, because
the bacteria have time to multiply, and the food does not
undergo a listericidal process, such as cooking, before con-
sumption. Unlike infection with other common foodborne
pathogens, listeriosis is associated with a high case-fatality
rate of approximately 20–30% [61]. Epidemiological investiga-
tions during the past 30 years have shown that epidemic lis-
teriosis and sporadic listeriosis are mainly caused by
consumption of contaminated food. Nevertheless, despite
the high rates of contamination of certain foods with L. mon-
ocytogenes, listeriosis is a relatively rare disease as compared
with other common foodborne illnesses, such as campylob-
acteriosis or salmonellosis. However, because of its high
case-fatality rate, listeriosis is, after salmonellosis, the second
most frequent cause of foodborne infection-related deaths in
Europe.
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